[18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy

Jennifer Lynn Whitwell, Val Lowe, Nirubol Tosakulwong, Stephen D. Weigand, Matthew L. Senjem, Christopher Schwarz, Anthony J. Spychalla, Ronald Carl Petersen, Clifford R Jr. Jack, Keith Anthony Josephs

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background: The [18F]AV-1451 positron emission tomography ligand allows the in vivo assessment of tau proteins in the brain. It shows strong binding in Alzheimer's dementia, but little is known about how it performs in progressive supranuclear palsy, a primary 4R tauopathy. Objectives: The objectives of this study were to determine whether [18F]AV-1451 uptake can be observed in progressive supranuclear palsy and to characterize the regional distribution when compared with controls and Alzheimer's dementia. Methods: [18F]AV-1451 positron emission tomography was performed in 10 patients with probable progressive supranuclear palsy. These patients were age- and gender-matched to 50 controls and 10 Alzheimer's dementia patients who had undergone identical [18F]AV-1451 imaging. Regional comparisons of [18F]AV-1451 uptake were performed across the whole brain using region-of-interest and voxel-level analyses, and correlations between regional [18F]AV-1451 and the progressive supranuclear palsy rating scale were assessed. Results: An elevated [18F]AV-1451 signal was observed in progressive supranuclear palsy when compared with controls in the pallidum, midbrain, dentate nucleus of the cerebellum, thalamus, caudate nucleus, and frontal regions. Signal in the cerebellar dentate and pallidum were also greater in progressive supranuclear palsy when compared with Alzheimer's dementia. Conversely, the [18F]AV-1451 signal across the cortex was higher in Alzheimer's dementia when compared with progressive supranuclear palsy. The [18F]AV-1451 signal in a number of regions correlated with the progressive supranuclear palsy rating scale. Conclusions: Progressive supranuclear palsy is associated with an elevated [18F]AV-1451 signal in a characteristic and distinct regional pattern that correlates with disease severity and differs from the patterns observed in Alzheimer's dementia.

Original languageEnglish (US)
JournalMovement Disorders
DOIs
StateAccepted/In press - 2016

Fingerprint

Progressive Supranuclear Palsy
Positron-Emission Tomography
Alzheimer Disease
Globus Pallidus
Tauopathies
Cerebellar Nuclei
tau Proteins
Caudate Nucleus
Brain
Mesencephalon
Thalamus
Cerebellum
Ligands

Keywords

  • Alzheimer's dementia
  • Positron emission tomography
  • Progressive supranuclear palsy
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

[18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. / Whitwell, Jennifer Lynn; Lowe, Val; Tosakulwong, Nirubol; Weigand, Stephen D.; Senjem, Matthew L.; Schwarz, Christopher; Spychalla, Anthony J.; Petersen, Ronald Carl; Jack, Clifford R Jr.; Josephs, Keith Anthony.

In: Movement Disorders, 2016.

Research output: Contribution to journalArticle

@article{c18440bf608346bf88522eb8120c4786,
title = "[18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy",
abstract = "Background: The [18F]AV-1451 positron emission tomography ligand allows the in vivo assessment of tau proteins in the brain. It shows strong binding in Alzheimer's dementia, but little is known about how it performs in progressive supranuclear palsy, a primary 4R tauopathy. Objectives: The objectives of this study were to determine whether [18F]AV-1451 uptake can be observed in progressive supranuclear palsy and to characterize the regional distribution when compared with controls and Alzheimer's dementia. Methods: [18F]AV-1451 positron emission tomography was performed in 10 patients with probable progressive supranuclear palsy. These patients were age- and gender-matched to 50 controls and 10 Alzheimer's dementia patients who had undergone identical [18F]AV-1451 imaging. Regional comparisons of [18F]AV-1451 uptake were performed across the whole brain using region-of-interest and voxel-level analyses, and correlations between regional [18F]AV-1451 and the progressive supranuclear palsy rating scale were assessed. Results: An elevated [18F]AV-1451 signal was observed in progressive supranuclear palsy when compared with controls in the pallidum, midbrain, dentate nucleus of the cerebellum, thalamus, caudate nucleus, and frontal regions. Signal in the cerebellar dentate and pallidum were also greater in progressive supranuclear palsy when compared with Alzheimer's dementia. Conversely, the [18F]AV-1451 signal across the cortex was higher in Alzheimer's dementia when compared with progressive supranuclear palsy. The [18F]AV-1451 signal in a number of regions correlated with the progressive supranuclear palsy rating scale. Conclusions: Progressive supranuclear palsy is associated with an elevated [18F]AV-1451 signal in a characteristic and distinct regional pattern that correlates with disease severity and differs from the patterns observed in Alzheimer's dementia.",
keywords = "Alzheimer's dementia, Positron emission tomography, Progressive supranuclear palsy, Tau",
author = "Whitwell, {Jennifer Lynn} and Val Lowe and Nirubol Tosakulwong and Weigand, {Stephen D.} and Senjem, {Matthew L.} and Christopher Schwarz and Spychalla, {Anthony J.} and Petersen, {Ronald Carl} and Jack, {Clifford R Jr.} and Josephs, {Keith Anthony}",
year = "2016",
doi = "10.1002/mds.26834",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - [18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy

AU - Whitwell, Jennifer Lynn

AU - Lowe, Val

AU - Tosakulwong, Nirubol

AU - Weigand, Stephen D.

AU - Senjem, Matthew L.

AU - Schwarz, Christopher

AU - Spychalla, Anthony J.

AU - Petersen, Ronald Carl

AU - Jack, Clifford R Jr.

AU - Josephs, Keith Anthony

PY - 2016

Y1 - 2016

N2 - Background: The [18F]AV-1451 positron emission tomography ligand allows the in vivo assessment of tau proteins in the brain. It shows strong binding in Alzheimer's dementia, but little is known about how it performs in progressive supranuclear palsy, a primary 4R tauopathy. Objectives: The objectives of this study were to determine whether [18F]AV-1451 uptake can be observed in progressive supranuclear palsy and to characterize the regional distribution when compared with controls and Alzheimer's dementia. Methods: [18F]AV-1451 positron emission tomography was performed in 10 patients with probable progressive supranuclear palsy. These patients were age- and gender-matched to 50 controls and 10 Alzheimer's dementia patients who had undergone identical [18F]AV-1451 imaging. Regional comparisons of [18F]AV-1451 uptake were performed across the whole brain using region-of-interest and voxel-level analyses, and correlations between regional [18F]AV-1451 and the progressive supranuclear palsy rating scale were assessed. Results: An elevated [18F]AV-1451 signal was observed in progressive supranuclear palsy when compared with controls in the pallidum, midbrain, dentate nucleus of the cerebellum, thalamus, caudate nucleus, and frontal regions. Signal in the cerebellar dentate and pallidum were also greater in progressive supranuclear palsy when compared with Alzheimer's dementia. Conversely, the [18F]AV-1451 signal across the cortex was higher in Alzheimer's dementia when compared with progressive supranuclear palsy. The [18F]AV-1451 signal in a number of regions correlated with the progressive supranuclear palsy rating scale. Conclusions: Progressive supranuclear palsy is associated with an elevated [18F]AV-1451 signal in a characteristic and distinct regional pattern that correlates with disease severity and differs from the patterns observed in Alzheimer's dementia.

AB - Background: The [18F]AV-1451 positron emission tomography ligand allows the in vivo assessment of tau proteins in the brain. It shows strong binding in Alzheimer's dementia, but little is known about how it performs in progressive supranuclear palsy, a primary 4R tauopathy. Objectives: The objectives of this study were to determine whether [18F]AV-1451 uptake can be observed in progressive supranuclear palsy and to characterize the regional distribution when compared with controls and Alzheimer's dementia. Methods: [18F]AV-1451 positron emission tomography was performed in 10 patients with probable progressive supranuclear palsy. These patients were age- and gender-matched to 50 controls and 10 Alzheimer's dementia patients who had undergone identical [18F]AV-1451 imaging. Regional comparisons of [18F]AV-1451 uptake were performed across the whole brain using region-of-interest and voxel-level analyses, and correlations between regional [18F]AV-1451 and the progressive supranuclear palsy rating scale were assessed. Results: An elevated [18F]AV-1451 signal was observed in progressive supranuclear palsy when compared with controls in the pallidum, midbrain, dentate nucleus of the cerebellum, thalamus, caudate nucleus, and frontal regions. Signal in the cerebellar dentate and pallidum were also greater in progressive supranuclear palsy when compared with Alzheimer's dementia. Conversely, the [18F]AV-1451 signal across the cortex was higher in Alzheimer's dementia when compared with progressive supranuclear palsy. The [18F]AV-1451 signal in a number of regions correlated with the progressive supranuclear palsy rating scale. Conclusions: Progressive supranuclear palsy is associated with an elevated [18F]AV-1451 signal in a characteristic and distinct regional pattern that correlates with disease severity and differs from the patterns observed in Alzheimer's dementia.

KW - Alzheimer's dementia

KW - Positron emission tomography

KW - Progressive supranuclear palsy

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84999749714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999749714&partnerID=8YFLogxK

U2 - 10.1002/mds.26834

DO - 10.1002/mds.26834

M3 - Article

C2 - 27787958

AN - SCOPUS:84999749714

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

ER -